Keryx Biopharmaceuticals (NASDAQ:KERX) is a company whose shares are active, trading 1.6% higher to $8.10. The S&P is currently trading fractionally higher to 1,676 and the Dow Jones Industrial Average is trading fractionally higher to 15,485.
Keryx Biopharmaceuticals (NASDAQ:KERX) has potential upside of 54.3% based on a current price of $8.10 and analysts' consensus price target of $12.50. The stock should find initial support at its 50-day moving average (MA) of $7.84 and further support at its 200-day MA of $5.52.
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinold compound for the treatment of diabetic nephropathy.
In the past 52 weeks, Keryx Biopharmaceuticals share prices have been bracketed by a low of $1.28 and a high of $9.98 and are now at $8.10, 533% above that low price. The 200-day and 50-day moving averages have moved 2.09% higher and 0.17% lower over the past week, respectively.